Genetic Determinants of Metabolic Biomarkers and their Associations with Cardiometabolic Traits in Hispanic/Latino Adolescents

Daeeun Kim, Anne E. Justice, Geetha Chittoor, Estela Blanco, Raquel Burrows, Mariaelisa Graff, Annie Green Howard, Yujie Wang, Rebecca Rohde, Victoria L. Buchanan, V. Saroja Voruganti, Marcio Almeida, Juan Peralta, Donna M. Lehman, Joanne E. Curran, Anthony G. Comuzzie, Ravindranath Duggirala, John Blangero, Cecilia Albala, José L. Santos, Bábara Angel, Betsy Lozoff, Sheila Gahagan, Kari E. North

1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
2. Department of Population Health Sciences, Geisinger, Danville, PA
3. Division of Academic General Pediatrics, Child Development and Community Health at the Center for Community Health, University of California at San Diego, San Diego, CA
4. Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
5. Department of Public Health Nutrition, Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile
6. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
7. Department of Nutrition and Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis NC
8. Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Brownsville, TX
Abstract

Background—Metabolic regulation plays a significant role in energy homeostasis, and adolescence is a crucial life-stage for the development of cardiometabolic disease (CMD).

Objectives—This study aims to investigate the genetic determinants of metabolic biomarkers—adiponectin, leptin, ghrelin, and orexin—and their associations with CMD risk factors.

Methods—We characterized the genetic determinants of the biomarkers among Hispanic/Latino adolescents of the Santiago Longitudinal Study (SLS) and identified the cumulative effects of genetic variants on adiponectin and leptin using biomarker polygenic risk scores (PRS). We further investigated the direct and indirect effect of the biomarker PRS on downstream body fat percent (BF%) and glycemic traits using structural equation modeling.

Results—We identified putatively novel genetic variants associated with the metabolic biomarkers. A substantial amount of biomarker variance was explained by SLS-specific PRS, and the prediction was improved by including the putatively novel loci. Fasting blood insulin and insulin resistance were associated with PRS for adiponectin, leptin, and ghrelin, and BF% was associated with PRS for adiponectin and leptin. We found evidence of substantial mediation of these associations by the biomarker levels.

Conclusion—The genetic underpinnings of metabolic biomarkers can affect the early development of CMD, partly mediated by the biomarkers.

INTRODUCTION

Obesity in early life and subsequent CMD is a major public health concern. In 2015-2016 in the US, one out of five adolescents aged 12-19 years were affected by obesity\(^1\) with a prevalence of 25.8% among self-identified Hispanic/Latino (H/L) youth (aged 2-19 years) compared to 14.1% among non-Hispanic white youth.\(^1\) Such alarming data are not restricted to the US H/L population, as many self-identified H/L populations in South and Central America are also suffering. For example, Chilean citizens also suffer from an increasing burden of obesity due to the epidemiological and nutritional transition that began in the 1980s.\(^2-3\)

Energy homeostasis is particularly critical in obesity biology\(^4\) since its related hormones play significant roles in balancing energy expenditure and energy intake by exchanging physiological information between the central nervous system and other parts of the body.\(^4,5\) In this regard, appetite-related metabolic hormones function as signaling molecules, and
malfunction of this system may interrupt energy homeostasis and consequently contribute to the development of obesity.

Four such metabolic hormones – adiponectin, leptin, ghrelin, and orexin – are involved in diverse cardiometabolic pathways. Adiponectin is well-known for its protective roles in appetite regulation, energy metabolism, diabetes, and inflammation.\textsuperscript{6} Leptin shows anorexigenic and proinflammatory roles; individuals with obesity tend to have higher levels of circulating leptin together with leptin resistance.\textsuperscript{7} Ghrelin is an appetite stimulating gut hormone that has been associated with glucose metabolism, which is closely linked to diabetes.\textsuperscript{8–11} Orexin is a hypothalamic neuropeptide that regulates feeding behaviors and arousal status\textsuperscript{12–14} and is ubiquitously expressed in different body sites\textsuperscript{15}, including plasma.\textsuperscript{16}

There is a paucity of information on the genetic determinants of metabolic biomarkers, particularly among adolescents and in H/L. Such work is critical as H/L have continental ancestry and admixture that is different than that found in European populations. Moreover, the interrelations among the genetic underpinnings of metabolic biomarkers, phenotypic variability, and downstream CMD risk factors (e.g., body fat percent (BF\%) and insulin resistance (IR)) among adolescents have also been understudied. Previous studies have revealed that some obesity-associated genetic factors are associated with appetite regulation\textsuperscript{17,18} and mendelian randomization studies have suggested causal relationships between metabolic biomarkers and CMD risk factors. However, studies focusing on the mediating roles of metabolic biomarkers in the relationship between the genetic underpinnings of metabolic biomarkers and CMD risk factors are lacking.

We sought to address these important gaps in the literature by first, describing the known and novel large-effect genetic determinants of the four metabolic biomarkers among H/L adolescents (Figure S1). Second, assessing the influence of aggregated genetic contributions to each biomarker by constructing polygenic risk scores (PRS) based on both known and novel genetic loci. Lastly, we aimed to investigate the relationship between the aggregated effects of biomarker-influencing genetic factors on obesity and glycemic traits, to estimate the degree to which this association is mediated by these biomarker levels. Investigating these relationships among adolescents with a high burden of obesity could provide critical insight into the biological mechanisms of obesity and downstream CMD during adolescence.

**METHODS**

**Study population**

The Santiago Longitudinal Study (SLS) originally began as a preventive trial for infancy iron deficiency anemia (IDA), funded by National Institutes of Health (NIH-R01 HD014122).\textsuperscript{19} From 1991 to 1996, a total of 1,792 infants were recruited at community clinics in lower/middle-class neighborhoods, in Santiago, Chile. Inclusion criteria for the infancy study were term singleton birth, vaginal delivery, birth weight \( \geq 3 \) kg, and absence of major perinatal health problems.\textsuperscript{19} Follow up studies occurred at 5, 10, and 16 years and included anthropometric measurement, psychosocial data, and developmental assessments.\textsuperscript{20,21} At 16 years, 679 adolescents completed a study of risk for obesity and
CMD that targeted participants with the most comprehensive data in childhood. Data collected included anthropometric measures, cardiovascular risk and metabolic biomarkers from fasting blood samples, and self-reported health-related behaviors. Complete phenotype and genotype data were available for 543 (80%) of these participants. The study was reviewed and approved or found to be exempt by Institutional Review Boards of the University of California at San Diego, University of Michigan, University of North Carolina at Chapel Hill, and the Institute of Nutrition and Food Technology, University of Chile.

Genetic data and quality control

Participants were genotyped on the Illumina Multiethnic Genotyping Array with imputation to the 1000 Genomes Phase III AMR reference panel. Quality control included individual call rate of > 90%, assessment of sex mismatch, relatedness, and ancestry outliers. Single nucleotide polymorphisms (SNPs) with effect allele frequency (EAF)<0.05, indels, and imputation quality score<0.5 were excluded, resulting in ~6 million SNPs that were assessed for their association with the biomarkers.

Measurement

Metabolic biomarkers.—Fasting blood samples were obtained, stored at −80°C, and analyzed. Enzyme-linked immunosorbent assay (ELISA) was used to measure adiponectin and leptin levels (R&D Systems, Minneapolis, MN and DRG International, Inc., New Jersey, NJ, respectively). The radioimmunoassay (RIA) technique was utilized to quantify ghrelin and orexin-A levels (Phoenix Pharmaceuticals, Inc., Burlingame CA).

BF%.—Dual energy x-ray absorptiometry (DEXA) scan was used to measure body fat mass (Lunar Prodigy Corp. Software: Lunar iDXA ENCORE 2011, Version 13.60.033, Madison, WI). BF% was calculated as [100(%) × fat mass(kg)/total body mass (kg)].

Glycemic traits.—From overnight fasting blood, glucose and insulin levels were quantified with an enzymatic colorimetric assay (QCA S.A., Amposta, Spain) and radioimmunoassay (RIA DCP Diagnostic Products Corporation, LA), respectively. In addition, IR was assessed based on continuous measure of homeostatic model assessment of insulin resistance (HOMA-IR; calculated as [(glucose (mg/dL) × insulin (μUI/dL))/405]; a value of HOMA-IR ≥2.6 can be diagnosed as insulin resistance.).

Analytical approach

Genome-wide association tests.—We regressed four metabolic biomarkers on SNPs using SUGEN, assuming an additive genetic model and adjusting for sex and population substructure using the first 5 principal components (PCs). PCs were constructed by EIGENSTRAT using genetic information of the participants. Serum adiponectin, ghrelin, and orexin levels were natural log-transformed before regression analyses. Due to a detection limit issue in measuring leptin levels, rank-based normalized residuals of a Tobit regression model adjusting for sex were used in the genome-wide association analyses for leptin levels. To correct for multiple testing, we considered SNPs with p-value <5 × 10⁻⁸ as demonstrating genome-wide significance, and those with a p-value <5 × 10⁻⁶ as demonstrating suggestive significance. We identified putative novel loci and reported...
the lead SNP from all 1 MB regions of the genome-wide significant and/or suggestive significant associations where no previous GWAS signal had been reported.

Validation of the GWAS findings.—For adiponectin and leptin levels, we investigated if the SNPs identified from SLS demonstrated similar associations in a separate Mexican American validation data set (see Supplementary Material for more information). We considered a signal to be validated if the same SNP was associated with the metabolic biomarker level at a Bonferroni-corrected significance level (p <0.05/the number of SNPs tested for validation for each biomarker) with directional consistency.

Functional interrogation of putative novel signals.—Among validated SNPs, we interrogated the potential candidate genes in each locus, selected based on 1) the evidence of functional link to a genetic locus (SNP) and 2) the previous reports on plausible gene functions. To examine the functional connection between a SNP and a gene, we queried the expression quantitative trait loci (eQTLs) from NIH Genotype-Tissue Expression (GTEx) project\(^25\) and biologically plausible gene functions using databases such as PubMed\(^a\), Online Mendelian Inheritance in Man\(^b\), and GeneCards\(^c\).

Transferability of known associations.—We described the transferability of known associations for adiponectin and leptin in SLS, defined when the association was reported with the exact SNP at nominal statistical significance (p <0.05) and directional consistency. As of 12/15/2020, there were 48 and 15 previously reported SNPs associated with adiponectin and leptin, respectively, at the genome-wide significance level. There were no previously reported SNPs associated with ghrelin or orexin levels at genome-wide significance.

Constructing PRS of adiponectin and leptin based on known and putative novel loci.—Given our small sample size and our desire to assess the evidence of mediated effects of genetic variants for these biomarkers on obesity and glycemic traits, we assessed the aggregated effects of previously reported genetic loci for adiponectin and leptin levels by constructing PRS. Since the previously reported SNPs were tag SNPs primarily identified in studies of Europeans, we considered three different approaches to PRS construction: 1) PRS constructed only by the previously reported SNPs (PRS\(_{\text{Reported}}\)), 2) PRS constructed by the SLS-specific tagging SNPs of the known loci (i.e., the lowest p-value within +/- 500kb of the previously reported SNPs) (PRS\(_{\text{SLS}}\)), and 3) PRS constructed by both SLS-specific previous signals and putatively novel signals from the current study (PRS\(_{\text{SLS+Novel}}\)). PRS\(_{\text{Reported}}\) was calculated by summing the number of biomarker-increasing alleles of the previously reported SNPs. If there were more than two SNPs in linkage disequilibrium (LD) (AMR \(r^2\) >0.2), we only included one tag SNP that was directionally consistent and had the lowest p-value among directionally consistent SNPs. If any of them were not directionally consistent, we included the SNP with the lowest p-value. PRS\(_{\text{SLS}}\) was defined as the number of biomarker-increasing alleles of the SLS-specific SNPs with the lowest p-values from the

\(^a\) https://pubmed.ncbi.nlm.nih.gov/
\(^b\) https://www.ncbi.nlm.nih.gov/omim
\(^c\) https://www.genecards.org/
current study among variants within +/- 500kb of the known SNPs. When we observed correlated SLS-specific SNPs (AMR $r^2>0.2$), we only included the SNP with the lower p-value for the association with the biomarker. PRS$_{SLS+Novel}$ was derived by summing up the PRS$_{SLS}$ and the number of biomarker-increasing alleles of the SNPs with genome-wide significance or suggestive significance from the current study.

**Investigating the associations between the adiponectin and leptin levels and the constructed PRS for the biomarker in the H/L population.**—We evaluated the aggregated genetic effects on adiponectin and leptin levels among SLS by regressing each biomarker (for adiponectin, ghrelin, and orexin, natural log-transformed values; for leptin, rank-based inverse normalized residuals of a Tobit regression adjusting for sex) on each PRS assuming a linear relationship and assessing prediction model by comparing $R^2$ (or adjusted $R^2$ for the models with covariates). Specifically, we compared four separate models for each biomarker as follows: a model only including PRS of the biomarker (Model 1), a model additionally including sex as a covariate (Model 2), a model additionally including the first five PCs as covariates (Model 3), and a model additionally including the BMI Z-score (Model 4).

**Investigating the relationship between the aggregated effects of biomarker influencing genetic factors on BF% and glycemic traits.**—Adjusting for sex and the first five PCs, we estimated the total effect of the metabolic biomarker PRS on BF% and glycemic traits (fasting blood glucose (FBG), fasting blood insulin (FBI), and IR) and the percent mediated through the biomarker levels using causal mediation analysis (PROC CAUSALMED) in SAS 9.4 (SAS Institute Inc., Cary, NC).26,27 The proposed pathways, both direct and indirect, from PRS to BF% and glycemic traits are shown in Figure S2. For adiponectin and leptin levels, all three types of PRS were investigated; for ghrelin and orexin levels only those suggestive signals identified in the GWAS herein were used. All pathways, including those to the biomarker and those to the cardiometabolic trait, were adjusted for sex and the first 5 PCs. To further account for the potential heterogeneities by sex, sex-stratified sensitivity analyses were conducted. In each stratified analysis, age and the first five PCs were included as covariates. For leptin, rank-based inverse normalized residuals of leptin from a Tobit regression adjusting for age were included as mediator. And for the other biomarkers, natural log-transformed biomarker levels were used as mediators. Statistical significance was determined using Bonferroni-corrected p-values. The results of sex-stratified analyses were presented in the supplementary tables (Table S12 – Table S15).

**RESULTS**

**Descriptive statistics.**

Table 1 reports the descriptive statistics from the 543 SLS participants (259 females) included in the current analyses. The average levels of adiponectin, leptin, ghrelin, and orexin were 11.3μg/mL (SD: 5.3), 11.7ng/mL (SD:13.5), 239.6pg/mL (SD: 151.0), and 16.7pg/mL (SD: 4.2), respectively. The descriptive characteristics of the validation sample are shown in Table S1.
Identification of novel signals.

No SNP-metabolic biomarker associations displayed genome-wide statistically significant evidence of association. However, 8, 5, 13, and 8 loci displayed suggestive associations with adiponectin, leptin, ghrelin, and orexin, respectively. The lead SNPs, nearest genes, and corresponding p-values for adiponectin, leptin, ghrelin, and orexin are reported in Table 2.

Validation of putative novel signal.

Ten of 13 adiponectin- or leptin-associated SNPs were available in the validation set. Of the examined genetic markers for validation (6 for adiponectin and 4 for leptin), only the marker rs12066716 was found to be significantly associated (Bonferroni-corrected p < 0.00625 (=0.05/8)) with adiponectin with directional consistency [β ± SE] in the discovery set: −0.181 ± 0.039, β ± SE] in the validation set: −0.191 ± 0.065]. The other 9 signals for adiponectin and leptin level were directionally consistent but not statistically significant (Table S2).

Functional interrogation of putative novel signals.

For our validated adiponectin-associated SNP (rs12066716), we identified a candidate gene demonstrating both functional links to an index SNP and plausible biological functions in determining adiponectin level. The index SNP (rs12066716) is an eQTL for C1QTNF12 (C1q/TNF-related protein 12, CTRP12) in visceral adipose tissue (p for eQTL = 8.1 × 10\(^{-5}\)). CTRPs, including CTRP12 (the product of C1QTNF12), are a family of adiponectin paralogs,\(^{28-30}\) thus the association between the gene and adiponectin is highly feasible.

Transferability of known associations.

For adiponectin, a total of 48 different SNPs have been reported for association with adiponectin from 11 studies\(^{31-41}\), 44 of which were available in the current study (Table S3). Thirty-five of these 44 SNPs displayed directionally consistent associations with adiponectin levels, 8 of which displayed nominal statistical significance (p<0.05). Fifteen variants have been associated with leptin levels with genome-wide significance from 3 studies\(^{42-44}\); 13 of these variants were available in the current study (Table S4). Six of these 13 associations were directionally consistent, but none were nominally significant (p<0.05).

Aggregated genetic influence on adiponectin and leptin levels

Adiponectin.—As some of the 44 available known SNPs are in LD with one another, we selected 29 independent SNPs (AMR LD \(r^2<0.2\)) and constructed PRS\(_{\text{Reported}}\) for adiponectin (Table S5). We also identified 24 independent SLS-specific tagging SNPs in the known loci by selecting the SNPs with lowest p-value for the association with adiponectin levels within ±500kb of the reported SNPs (Table S7). All the 24 SLS-specific tagging SNPs were independent of each known SNP (AMR LD \(r^2<0.2\)). Using these 24 SLS-specific tagging SNPs for the known loci, we generated PRS\(_{\text{SLS}}\). Lastly, we additionally summed up the number of adiponectin-increasing alleles of the 8 putative novel variants from the PRS\(_{\text{SLS}}\) and generated adiponectin-PRS\(_{\text{SLS+Novel}}\). The prediction results of the natural log-

\(\beta \) https://www.gtexportal.org/home/snp/rs12066716
transformed adiponectin levels by PRS were reported in Table 3. While the proportion of variance explained by PRS\textsubscript{Reported} was 0.035, the proportion of variance explained by PRS\textsubscript{SLS} was 0.253 (Table 3). We further estimated the proportion of variance explained by PRS\textsubscript{SLS+Novel} from the current study as 0.367. While the estimated variance explained is likely to be biased upward because of winner’s curse, it is obvious that the SLS-specific tagging SNPs better characterized the genetic effects of these loci on this biomarker (also below for leptin) for our SLS population.

**Leptin.**—Among the 13 available known SNPs, we selected 7 independent SNPs (AMR LD $r^2 <0.2$) and constructed PRS\textsubscript{Reported} for leptin levels (Table S6). We also identified 8 SLS-specific tagging SNPs of the known loci – i.e., SNPs with the lowest p-values within +/- 500kb of the known variant – and constructed PRS\textsubscript{SLS} for leptin levels (Table S8). All the 8 SLS-specific tagging SNPs are independent of the known SNPs (AMR LD $r^2<0.2$). Then, we summed up the number of leptin-increasing alleles of the 5 putative novel variants from the PRS\textsubscript{SLS} and calculated PRS\textsubscript{SLS+Novel}. We predicted the rank-based normalized residuals of Tobit regressed leptin level (sex as an explanatory variable) by using the three PRS (Table 3). Whereas the variance explained by PRS\textsubscript{Reported} was 0.001 (and the regression coefficient was not significant with a significance level of 0.05), the variance explained by PRS\textsubscript{SLS} was 0.082 and by PRS\textsubscript{SLS+Novel} was 0.206 (Table 3). It is possible that the $R^2$ for leptin was lower than for adiponectin partly due to fewer previous GWAS of leptin than adiponectin.

**Effects of the biomarker-associated genetic determinants on downstream BF% and glycemic traits**

**Adiponectin.**—FBI (p=0.0037), IR (p=0.0064) and BF% (p<0.0001) were significantly associated with PRS\textsubscript{SLS+Novel} (Table 4). For FBI and IR, significant indirect effects (i.e., mediated through adiponectin levels) were noted. The mediated effects of adiponectin PRS\textsubscript{SLS+Novel} on FBI and IR accounted for 79.0% (95% CL: 2.4, 155.5; p=0.04) and 83.2% (95% CL: −0.5, 166.8; p=0.05) of the overall effects, respectively. For BF%, we also found evidence of mediation, but the proportion of mediated effects over the total effects was only 46.7% (95% CL: 2.4, 90.9; p=0.04). Given the wide confidence interval of these estimates, point estimate should be interpreted with caution. In terms of direction of effects, both directly and indirectly the adiponectin-increasing effects appeared to be metabolically protective (decrease in FBI, IR, and BF%). For PRS\textsubscript{SLS}, the total effects on FBI and BF% were estimated as being significant as for PRS\textsubscript{SLS+Novel}, but for PRS\textsubscript{Reported} none of them was significantly affected by the PRS (Table S9).

**Leptin.**—FBI (p=0.0014), IR (p=0.0043), and BF% (p<0.0001) were significantly affected by the leptin PRS\textsubscript{SLS+Novel} (Table 4). The total effect of leptin-increasing PRS was associated with poorer metabolic outcomes (i.e., increase in FBI, IR, and BF%). For FBI and IR, the estimate of the direct effect of PRS on leptin was negative and the estimate of the indirect effect of PRS on the CMD health outcome through leptin was positive. Therefore, the indirect pathway through leptin accounted for most of this association between FBI and IR. For BF%, where both direct and indirect associations were positive, the proportion of mediated effects was 96.9% (95% CL: 65.2, 128.5; p<0.01). For PRS\textsubscript{SLS}, only the total
effect on BF% was significant (also associated with worse metabolic outcomes); none of the hypothetical downstream BF% and glycemic traits were significantly associated with PRS Reported (Table S10). According to the results from sex-stratified analyses, the total effects of leptin PRS_{SLS+Novel} on FBI and IR are largely driven by females, however, the indirect effects mediated through leptin are comparable—in terms of direction, magnitude, and significance—among females and males (Table S13).

**Ghrelin.**—FBI (p<0.0001) and IR (p<0.0001) were significantly affected by the ghrelin PRS based on the putative novel variants from the current study (Table 4) with ghrelin-increasing PRS associated with overall decreases in IR. As with leptin, we found differences in the direction of the association between direct and indirect effects. Higher PRS were indirectly related with lower FBG (−0.223 [95% CI: (−0.286, −0.161)]) and IR (−0.232 [95% CI: (−0.295, −0.169)]), and the total association was similar in magnitude even after accounting for the direct effects.

**Orexin.**—None of the cardiometabolic traits were affected by the orexin-increasing PRS (Table 4).

**DISCUSSION**

The identification of genetic mechanisms influencing metabolic biomarkers has the potential to identify important pathways for obesity and its downstream consequences. Yet, the bulk of obesity research has focused on how genes relate to BMI and waist circumference, instead of on relationships with eating behaviors and/or mechanistic biomarkers which may have early influences on the development of obesity, through appetite for example. Further still, most extant data has primarily focused on homogeneous middle-aged adults, with very few genetic studies on culturally and ancestrally diverse adolescents. The current study identified 34 suggestive novel genetic signals associated with four metabolic biomarkers and validated one novel signal associated with adiponectin level. In addition, we revealed that associations between biomarkers and aggregated genetic effects based on known variants were improved when study-specific tag SNPs for known loci and novel variants were included in the PRS. This implicates the need for ancestry-specific studies to validly capture aggregated genetic effects across populations. Lastly, we demonstrated that metabolic biomarker-influencing genetic factors were also associated with some CMD risk factors, especially with FBI and IR (for adiponectin, leptin, and ghrelin) and BF% (for adiponectin and leptin), implicating causal roles of these biomarkers in obesity and IR as early as adolescence.

Although our study did not demonstrate novel genome-wide significant signals for appetite markers, likely due to insufficient power, 34 putative novel signals with suggestive evidence for association with metabolic biomarkers were mapped, with the rs12066716 adiponectin association validated in a H/L adult population (p<0.00625) despite the age differences between the two study populations. While the SNP is intronic to TTL10, it is associated with gene expression in several other nearby genes in adipose tissue. Notably, rs12066716 is an eQTL for C1QTNF12, which encodes CTRP12 (also called adipolin), a member of the family of adiponectin paralogs.\(^{(28,30,45,46)}\) CTRP12 improves insulin sensitivity\(^{(29}\) and has
been shown to correlate with adiponectin levels (r=0.34) In addition, CTRP12 levels are currently being evaluated as a diagnostic biomarker for T2D Finally, other studies have demonstrated that CTRP12 levels were lower among patients with coronary artery disease.

We found that little to none of the variance in adiponectin and leptin levels were explained by PRS based on the exact reported SNPs from the literature, likely due to the ancestral difference between our population (i.e., mainly European vs. H/L) and published studies. Once we substituted SLS-specific tagging SNPs of the known loci for the reported SNPs, the prediction performance of the PRS improved substantially (R$^2$ 0.035 to 0.253 for adiponectin and 0.001 to 0.082 for leptin). We conducted permutation testing to place our adiponectin-PRS$_{SLS}$ findings in context. We randomly selected 24 SNPs among all SNPs that displayed significant association (p<0.05) with adiponectin in our GWAS. We then constructed the PRS (the number of risk alleles) from each these SNPs and calculated the R-square values from each model. Repeating this simulation 1000 times, we observed the distribution of R-square values (maximum: 0.220; range: 0.125 – 0.220; Figure S4). All R-square values were of smaller magnitude than our adiponectin-PRS$_{SLS}$ estimate (0.253). Thus, our results demonstrate that the proportion of variation explained by adiponectin-PRS$_{SLS}$ was greater than chance, likely an overestimation as well. This finding demonstrates the need for valid ancestry-specific tagging SNPs for PRS. Furthermore, since we identified additional improvement of PRS' performance after incorporating the putative novel signals, large-scale studies for diverse populations to discover additional genetic loci associated with metabolic biomarker are warranted. However, it should be noted that the predictions by PRSSLS and PRS$_{SLS+Novel}$ were likely to be overestimated because of the overlap between the discovery set of the associations and the validation set for the association. Nonetheless, as illustrated in our previous study, the current findings also underscore the importance of considering genetic diversity across different cohorts, and the influence of this diversity on unique underpinnings to disease in future application of PRS to diverse ethnic groups.

For adiponectin, leptin, and ghrelin, PRS of biomarkers were simultaneously associated with FBI, IR and BF% (except for ghrelin) among H/L adolescents. These common associations may suggest shared genetic pathways, at least to a certain degree, between metabolic biomarkers and CMD as early as adolescence. Many of the significant overall effects included significant mediated effect by metabolic biomarkers (FBI, IR, and BF% for leptin and adiponectin, and FBI and IR for ghrelin), and this implies that each metabolic biomarker might be somewhere on the causal pathways from the biomarker-determining genetic factors to the CMD risk factors—i.e., the metabolic biomarkers are causally associated with the CMD risk factors—if our assumption on the hypothetical causal relationship (see Figure S2) is valid. Notably, FBI and IR are closely associated with PRS for adiponectin, leptin, and ghrelin through indirect effects. Since IR is considered a root cause of various CMD, it is crucial to elucidate the roles of these metabolic biomarkers in developing IR. For the significant mediated effects on BF% for adiponectin and leptin, our findings also suggest an early causal effect of adiponectin and leptin on body fat, suggesting an importance of these biomarkers for the development of obesity at a very young age. Such findings may have relevance for the timing of planning interventions.
The observed significant indirect effects on FBI, IR, and BF% support the protective roles of adiponectin in cardiometabolic health. While inverse associations of plasma adiponectin with IR and adiposity have been well established, the findings from mendelian randomization studies to assess the causal relationships between adiponectin and IR (or insulin sensitivity) and between adiponectin and BMI have been contradictory or unsupported. Such findings may be related to weak genetic instruments, population stratification bias, genetic pleiotropy, and LD. Although our analysis has not formally assessed causal relationships between these biomarkers, our data support a potential influence of adiponectin on FBI, IR, and BF% by the presence of significant indirect effects of adiponectin-associated genetic factors mediated by adiponectin levels. In addition, for BF%, the effect sizes of the direct (β = −0.072 despite not meeting the significance criteria; p = 0.084) and indirect effect (β = −0.063, p = 0.018) were comparable. This implies the presence of other pathways from the adiponectin-associated genes to BF% independent of adiponectin. Further studies investigating potential common pathways shared between BF% and adiponectin levels are needed.

For the downstream effect of leptin-influencing genetic variants on adiposity, a previous study reported that a leptin-decreasing allele (rs17151919-A) was associated with higher BMI during early childhood (under 8-year). However, our results demonstrated a leptin-increasing PRS was associated with higher BF%. Such results may be understood in the context of distinct leptin effects across the life-course and in the context of poor cardiometabolic health. Although leptin typically inhibits appetite and increases energy expenditure, individuals with poor cardiometabolic health tend to have higher circulating leptin levels due to low leptin sensitivity – i.e., leptin resistance. Since the previous study and our results focused on early childhood and late adolescence, respectively, the opposite direction of the association between leptin-influencing genetic variants and adiposity might have been driven by the development of leptin resistance.

For ghrelin, similar patterns with adiponectin were demonstrated except for BF%. This implicates the potential protective roles of circulating ghrelin in cardiometabolic traits especially for insulin biology. In line with this finding, many previous studies including a meta-analysis on the association between ghrelin and IR in obesity reported the negative correlation among people with obesity. Thus, our study adds to the body of literature that supports ghrelin’s role in glucose metabolism, but the mechanisms by which circulating ghrelin levels play roles in regulating insulin sensitivity need to be further studied.

Overall, our results contribute to the mechanistic evidence of obesity-risk genes influencing adiposity via the appetite regulatory system, as previously shown for monogenic obesity disorders, which, without exception, involve disturbances of appetite leading to severe early-onset obesity. A substantial evidence base of prospective studies links impaired satiety mechanisms to excessive weight gain, and bivariate twin analyses are consistent with common genetic pathways underlying satiety responsiveness and weight in infancy. This suggests that genetically susceptible individuals are particularly vulnerable to the abundance of highly palatable food in the modern obesogenic environment.
The major strength of this study is the availability of four metabolic biomarkers in an adolescent H/L population at high risk for obesity and downstream CMD. In particular, genome-wide studies of ghrelin and orexin are rare. For adiponectin and leptin, we also leveraged the known information from the previous studies to assess the aggregated genetic effects. Lastly, we extensively investigated cross-trait associations of biomarker-influencing genetic loci with other CMD risk factors. There are notable limitations to our study, including the modest sample size and the lack of availability of studies to replicate our findings. Nine out of 10 putative novel signals for adiponectin and leptin level were not replicated from the validation data set, which could be related to the distinct admixture patterns across Mexican Americans and Chileans, the differences in age across the data sets, or small sample sizes. In addition, PRS<sub>SLS</sub> and PRS<sub>SLS+Novel</sub> may have overestimated the aggregated genetic effects and cross-trait associations with BF%, FBI, and IR. Furthermore, as analyses were conducted cross-sectionally, it is difficult to determine temporality among traits, e.g., metabolic biomarkers and cardiometabolic traits, and the possibilities of reverse causation between biomarker level and cardiometabolic traits.

In conclusion, our study identified several putatively novel genetic variants associated with the metabolic biomarkers with substantial phenotypic variance explained by SLS-specific PRS. We also demonstrated that some of the aggregated genetic factors may be directly linked to BF%, FBI, and IR or mediated through metabolic biomarkers. Our findings reinforce a need for longitudinal analyses to confirm the genetic determinants regulating metabolic homeostasis and their further influence on cardiometabolic disorder development. From a public health standpoint, such findings are critical, as once cardiometabolic health is established in adolescence, it is very difficult to reverse. Thus, findings from this study yielded important information on biological mechanisms and candidates for prevention efforts, especially relevant in this high-risk ancestrally diverse population.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Statement of Financial Support**

This work was funded in part by University of North Carolina Nutrition Research Institute internal pilot grant, AHA grant 15GRNT25880008 and NIH award K99/R00HL130580-02. We thank the participants and their family members from the Santiago Longitudinal Study (SLS) (R01 HL088530, R01 HD33487). Dr. North is additionally supported by R01HL151152 and R01 DK122503.

Work for the validation study was supported in part by National Institutes of Health (NIH) grants P01 HL045522, R01 DK047482, DK053889, R01 HL113323, R37 MH059490, and T2D-GENES Consortium grants (U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526, and U01 DK085545). We thank the participants of the San Antonio Family Heart Study and the San Antonio Family Diabetes/Gallbladder Study for their continued cooperation and participation in our research programs.

**REFERENCES**

1. Hales CM, Carroll MD, Fryar CD, & Ogden CL, Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. NCHS data brief, 1–8 (2017).
2. Albala C, Vio F, Kain J, & Uauy R, Nutrition transition in Chile: determinants and consequences. Public Health Nutr 5, 123–128, doi:10.1079/PHN2001283 (2002). [PubMed: 12027274]
3. Muzzo S, Burrows R, Cordero J, & Ramirez I, Trends in nutritional status and stature among school-age children in Chile. Nutrition 20, 867–872, doi:10.1016/j.nut.2004.06.007 (2004). [PubMed: 15474874]

4. Ghanemi A, Yoshioka M, & St-Amand J, Broken Energy Homeostasis and Obesity Pathogenesis: The Surrounding Concepts. Journal of Clinical Medicine 7, 453–453, doi:10.3390/jcm7110453 (2018).

5. Richard D, Cognitive and autonomic determinants of energy homeostasis in obesity. Nat Rev Endocrinol 11, 489–501, doi:10.1038/nrendo.2015.103 (2015). [PubMed: 26122319]

6. Nigro E et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014, 658913, doi:10.1155/2014/658913 (2014). [PubMed: 25110685]

7. Abella V et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol 13, 100–109, doi:10.1038/nrrheum.2016.209 (2017). [PubMed: 28053336]

8. Chabot F, Caron A, Laplante M, & St-Pierre DH, Interrelationships between ghrelin, insulin and glucose homeostasis: Physiological relevance. World J Diabetes 5, 328–341, doi:10.4239/ wjd.v5.i3.328 (2014). [PubMed: 24936254]

9. Gray SM, Page LC, & Tong J, Ghrelin regulation of glucose metabolism. J Neuroendocrinol 31, e12705, doi:10.1111/jne.12705 (2019). [PubMed: 30849212]

10. Klok MD, Jakobsdottir S, & Drent ML, The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obesity reviews: an official journal of the International Association for the Study of Obesity 8, 21–34, doi:10.1111/j.1467-789X.2006.00270.x (2007). [PubMed: 17212793]

11. Poher AL, Tschöp MH, & Müller TD, Ghrelin regulation of glucose metabolism. Peptides 100, 236–242, doi:10.1016/j.peptides.2017.12.015 (2018). [PubMed: 29412824]

12. Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, & Williams AJ, The hypocretin/orexin system. J R Soc Med 95, 227–230, doi:10.1258/jrsm.95.5.227 (2002). [PubMed: 11983761]

13. Lin L et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365–376, doi:10.1016/S0092-8674(00)81965-0 (1999). [PubMed: 10458611]

14. Sakurai T et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585, doi:10.1016/S0092-8674(00)80949-6 (1998). [PubMed: 9491897]

15. Heinonen MV, Purhonen AK, Makela KA, & Herzig KH, Functions of orexins in peripheral tissues. Acta Physiol (Oxf) 192, 471–485, doi:10.1111/j.1748-1716.2008.01836.x (2008). [PubMed: 18294339]

16. Arihara Z et al. Immunoreactive orexin-A in human plasma. Peptides 22, 139–142, doi:10.1016/S0196-9781(00)00369-7 (2001). [PubMed: 11179609]

17. Cecil JE, Tavendale R, Watt P, Hetherington MM, & Palmer CN, An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 359, 2558–2566, doi:10.1056/NEJMoa0803839 (2008). [PubMed: 19073975]

18. Llewellyn CH, Trzaskowski M, van Jaarsveld CHM, Plomin R, & Wardle J, Satiety mechanisms in genetic risk of obesity. JAMA Pediatr 168, 338–344, doi:10.1001/jamapediatrics.2013.4944 (2014). [PubMed: 24535189]

19. Lozoff B et al. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. Pediatrics 112, 846–854 (2003). [PubMed: 14523176]

20. East P et al. Infant iron deficiency, child affect, and maternal unresponsiveness: Testing the long-term effects of functional isolation. Developmental psychology 53, 2233–2244, doi:10.1037/ dev0000385 (2017). [PubMed: 28933876]

21. Pacheco LS et al. Early onset obesity and risk of metabolic syndrome among Chilean adolescents. Preventing Chronic Disease 14, doi:10.5888/pcd14.170132 (2017).

22. Burrows R et al. Healthy Chilean Adolescents with HOMA-IR >= 2.6 Have Increased Cardiometabolic Risk: Association with Genetic, Biological, and Environmental Factors. Journal of Diabetes Research 2015, doi:Artn 783296 10.1155/2015/783296 (2015).
23. Lin DY et al. Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet 95, 675–688, doi:10.1016/j.ajhg.2014.11.005 (2014). [PubMed: 25480034]

24. Price AL et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904–909, doi:10.1038/ng1847 (2006). [PubMed: 16862161]

25. Consortium GT, The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 580–585, doi:10.1038/ng.2653 (2013). [PubMed: 23715323]

26. VanderWeele TJ Explanation in causal inference : methods for mediation and interaction. (Oxford University Press, 2015).

27. VanderWeele TJ, & Vansteelandt S, Conceptual issues concerning mediation, interventions and composition. Stat Interface 2, 457–468 (2009).

28. Enomoto T et al. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. Journal of Biological Chemistry 286, 34552–34558, doi:10.1074/jbc.M111.277319 (2011). [PubMed: 21849507]

29. Wei Z et al. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. Journal of Biological Chemistry 287, 10301–10315, doi:10.1074/jbc.M111.303651 (2012). [PubMed: 22275362]

30. Wong GW, Wang J, Hug C, Tsao TS, & Lodish HF, A family of Acrp30/adiponectin structural and functional paralogs. Proceedings of the National Academy of Sciences of the United States of America 101, 10302–10307, doi:10.1073/pnas.0403760101 (2004). [PubMed: 15231994]

31. Chung CM et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes 60, 2417–2423, doi:10.2337/db10-1321 (2011). [PubMed: 21771975]

32. Heid IM et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis 208, 412–420, doi:10.1016/j.atherosclerosis.2009.11.035 (2010). [PubMed: 20018283]

33. Morisaki H et al. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Hum Mutat 33, 402–410, doi:10.1002/humu.21652 (2012). [PubMed: 22065538]

34. Spracklen CN et al. Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology. Am J Hum Genet 105, 15–28, doi:10.1016/j.ajhg.2019.05.002 (2019). [PubMed: 31178129]

35. Wu Y et al. A meta-analysis of genome-wide association studies for adiponectin levels in East Asians identifies a novel locus near WDR11-FGFR2. Hum Mol Genet 23, 1108–1119, doi:10.1093/hmg/ddt488 (2014). [PubMed: 24105470]

36. Dastani Z et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 8, e1002607, doi:10.1371/journal.pgen.1002607 (2012). [PubMed: 22479202]

37. Qi L et al. Novel locus FER is associated with serum HMW adiponectin levels. Diabetes 60, 2197–2201, doi:10.2337/db10-1645 (2011). [PubMed: 21700879]

38. Jee SH et al. Adiponectin concentrations: a genome-wide association study. Am J Hum Genet 87, 545–552, doi:10.1016/j.ajhg.2010.09.004 (2010). [PubMed: 20887962]

39. Wu Y et al. Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Hum Mol Genet 19, 4955–4964, doi:10.1093/hmg/ddq423 (2010). [PubMed: 20876611]

40. Richards JB et al. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet 5, e1000768, doi:10.1371/journal.pgen.1000768 (2009). [PubMed: 20011104]

41. Ling H et al. Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) 17, 737–744, doi:10.1038/oby.2008.625 (2009). [PubMed: 19165155]

42. Folkersen L et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab 2, 1135–1148, doi:10.1038/s42255-020-00287-2 (2020). [PubMed: 33067605]
43. Kilpelainen TO et al. Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nat Commun 7, 10494, doi:10.1038/ncomms10494 (2016). [PubMed: 26833098]
44. Yaghootkar H et al. Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity. Diabetes 69, 2806–2818, doi:10.2337/db20-0070 (2020). [PubMed: 32917775]
45. Sargolzaei J, Chamani E, Kazemi T, Fallah S, & Soori H, The role of adiponectin and adipolin as anti-inflammatory adipokines in the formation of macrophage foam cells and their association with cardiovascular diseases. Clin Biochem 54, 1–10, doi:10.1016/j.clinbiochem.2018.02.008 (2018). [PubMed: 29452073]
46. Schaffler A, & Buechler C, CTRP family: linking immunity to metabolism. Trends Endocrinol Metab 23, 194–204, doi:10.1016/j.tem.2011.12.003 (2012). [PubMed: 22261190]
47. Fadai R et al. Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance. Cytokine 113, 326–331, doi:10.1016/j.cyto.2018.09.019 (2019). [PubMed: 30337217]
48. Bai B et al. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. PLoS ONE 12, doi:10.1371/journal.pone.0172271 (2017).
49. Justice AE et al. Genetic determinants of BMI from early childhood to adolescence: the Santiago Longitudinal Study. Pediatr Obes 14, e12479, doi:10.1111/ijpo.12479 (2019). [PubMed: 30515969]
50. Carlson CS et al. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol 11, e1001661, doi:10.1371/journal.pbio.1001661 (2013). [PubMed: 24068893]
51. Ginsberg HN, Insulin resistance and cardiovascular disease. J Clin Invest 106, 453–458, doi:10.1172/JCI10762 (2000). [PubMed: 10953019]
52. Arita Y et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 425, 560–564, doi:10.1016/j.bbrc.2012.08.024 (2012). [PubMed: 22925674]
53. Tilg H, & Moschen AR, Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772–783, doi:10.1038/nri1937 (2006). [PubMed: 16998510]
54. Borges MC et al. Metabolic Profiling of Adiponectin Levels in Adults: Mendelian Randomization Analysis. Circ Cardiovasc Genet 10, doi:10.1161/CIRCGENETICS.117.001837 (2017).
55. Yaghootkar H et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62, 3589–3598, doi:10.2337/db13-0128 (2013). [PubMed: 23835345]
56. Mente A et al. Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. PLoS One 8, e66808, doi:10.1371/journal.pone.0066808 (2013). [PubMed: 23826141]
57. Gao H et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 62, 1338–1344, doi:10.2337/db12-0935 (2013). [PubMed: 23274890]
58. Nielsen MB, Colak Y, Benn M, & Nordestgaard BG, Causal Relationship between Plasma Adiponectin and Body Mass Index: One- and Two-Sample Bidirectional Mendelian Randomization Analyses in 460 397 Individuals. Clin Chem, doi:10.1093/clinchem/hvaa227 (2020).
59. Farooqi IS et al. Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency. New England Journal of Medicine 341, 879–884, doi:10.1056/NEJM199909163411204 (1999). [PubMed: 10486419]
60. Myers MG, Cowley MA, & Munzberg H, Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70, 537–556, doi:10.1146/annurev.physiol.70.113006.100707 (2008). [PubMed: 17937601]
61. Zhang CS et al. The Correlation Between Circulating Ghrelin and Insulin Resistance in Obesity: A Meta-Analysis. Frontiers in Physiology 9, doi:ARTN 1308 10.3389/fphys.2018.01308 (2018).
62. Montague CT et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387, 903–908, doi:10.1038/43185 (1997). [PubMed: 9202122]
63. van Jaarsveld CH, Boniface D, Llewellyn CH, & Wardle J, Appetite and growth: a longitudinal sibling analysis. JAMA Pediatr 168, 345–350, doi:10.1001/jamapediatrics.2013.4951 (2014). [PubMed: 24535222]

64. van Jaarsveld CH, Llewellyn CH, Johnson L, & Wardle J, Prospective associations between appetitive traits and weight gain in infancy. Am J Clin Nutr 94, 1562–1567, doi:10.3945/ajcn.111.015818 (2011). [PubMed: 22071702]

65. Parkinson KN, Drewett RF, Le Couteur AS, Adamson AJ, & Gateshead Millennium Study Core, T. Do maternal ratings of appetite in infants predict later Child Eating Behaviour Questionnaire scores and body mass index? Appetite 54, 186–190, doi:10.1016/j.appet.2009.10.007 (2010). [PubMed: 19887093]

66. Llewellyn CH, van Jaarsveld CH, Plomin R, Fisher A, & Wardle J, Inherited behavioral susceptibility to adiposity in infancy: a multivariate genetic analysis of appetite and weight in the Gemini birth cohort. Am J Clin Nutr 95, 633–639, doi:10.3945/ajcn.111.023671 (2012). [PubMed: 22277555]
Impact

- This study characterized the genetic underpinnings of four metabolic hormones and investigated their potential influence on adiposity and insulin biology among Hispanic/Latino adolescents.

- Fasting blood insulin and insulin resistance were associated with polygenic risk score (PRS) for adiponectin, leptin, and ghrelin, with evidence of some degree of mediation by the biomarker levels. Body fat percent (BF%) was also associated with PRS for adiponectin and leptin. This provides important insight on biological mechanisms underlying early metabolic dysfunction and reveals candidates for prevention efforts.

- Our findings also highlight the importance of ancestrally diverse populations to facilitate valid studies of the genetic architecture of metabolic biomarker levels.
Table 1.
Distributions of variables among 16-year follow-up of the Santiago Longitudinal Study (SLS)

| Variable                        | Total (N=543) |
|---------------------------------|---------------|
|                                 | Mean | SD  |
| Age (years)                     | 16.8 | 0.3 |
| **Anthropometric variables**    |      |     |
| Body Mass Index (BMI) (kg/m²)   | 23.8 | 4.6 |
| BMI Z-scores                    | 0.5  | 1.0 |
| **Metabolic biomarkers**        |      |     |
| Adiponectin (μg/mL)             | 11.3 | 5.3 |
| Leptin (ng/mL)                  | 11.7 | 13.5|
| Ghrelin (pg/mL)                 | 239.6| 151.0|
| Orexin (pg/mL)                  | 16.7 | 4.2 |
| **Glycemic traits**             |      |     |
| Fasting blood glucose (mg/dL)   | 88.4 | 9.8 |
| Fasting blood insulin (μUI/dL)  | 8.1  | 5.6 |
| Insulin resistance [HOMA-IR<sup>c</sup> (glucose × insulin/405)] | 1.8  | 1.3 |
| **Body fat percent (%)** (N=537; 5 missing females and 1 missing male) | 28.9 | 10.7 |

<sup>a</sup> 259 females (47.7%) and 284 males (52.3%)
<sup>b</sup> Leptin levels in females: 18.8 ng/mL (SD: 14.7); leptin levels in males: 5.2 ng/mL (SD: 8.0)
<sup>c</sup> HOMA-IR: homeostatic model assessment of insulin resistance
Table 2.
Lead SNPs with suggestive significance (p < 5.00E-06) associated with four appetite/metabolic biomarkers from the GWA analyses in participants of SLS

| GWAS Traits | Nearest gene | Lead SNP | CHR | BP   | EA/OA | EAF   | BETA   | SE   | p-value   |
|-------------|--------------|----------|-----|-------|-------|-------|--------|------|-----------|
| Adiponectin | TTLL10       | rs12066716$^a$ | 1   | 1123434 | A/T   | 0.17  | −0.181 | 0.039 | 3.04E-06  |
|             | AK5          | rs59559185  | 1   | 77825925 | A/G   | 0.18  | 0.182  | 0.039 | 2.55E-06  |
|             | LRRC8C       | rs17130858  | 1   | 90167923 | G/A   | 0.25  | 0.158  | 0.033 | 1.38E-06  |
|             | C3orf31      | rs407484    | 3   | 11944316 | A/T   | 0.10  | −0.271 | 0.053 | 4.00E-07  |
|             | VCAN         | rs33601     | 5   | 82773175 | A/G   | 0.66  | 0.144  | 0.031 | 4.94E-06  |
|             | CLDN10       | rs2992893   | 13  | 96044769 | C/T   | 0.52  | −0.148 | 0.030 | 7.02E-07  |
|             | FLJ22447     | rs17098985  | 14  | 62092745 | T/C   | 0.13  | −0.236 | 0.045 | 1.29E-07  |
|             | PNMAL1       | rs11083829  | 19  | 46967169 | C/A   | 0.74  | −0.174 | 0.036 | 1.48E-06  |
| Leptin      | ZNF804B      | rs34056816  | 7   | 89190522 | C/T   | 0.06  | 0.748  | 0.161 | 3.47E-06  |
|             | SQRDL (SQOR) | rs8026541   | 15  | 46695491 | T/C   | 0.72  | 0.367  | 0.069 | 1.14E-07  |
|             | CDH5         | rs233521    | 16  | 66282923 | A/G   | 0.80  | 0.350  | 0.076 | 4.29E-06  |
|             | LOC100506172 | rs77137714  | 16  | 73378933 | T/C   | 0.14  | 0.409  | 0.088 | 3.70E-06  |
|             | MIR4739      | rs6206332   | 17  | 77635587 | G/A   | 0.09  | −0.567 | 0.124 | 4.64E-06  |
| Ghrelin     | LOC1001203138| rs12144587  | 1   | 106005238| G/T   | 0.56  | −0.154 | 0.033 | 4.07E-06  |
|             | ADAM30       | rs76491617  | 1   | 12043439 | C/T   | 0.15  | −0.239 | 0.051 | 2.80E-06  |
|             | FSEN2        | rs67899970  | 1   | 22709266 | T/C   | 0.14  | 0.228  | 0.049 | 4.05E-06  |
|             | CNTNAP5      | rs181846169 | 2   | 124237624| T/C   | 0.05  | 0.419  | 0.087 | 1.24E-06  |
|             | KCNH8        | rs4535245   | 3   | 19541306 | A/G   | 0.14  | −0.222 | 0.048 | 3.86E-06  |
|             | NNXPH1       | rs6966968   | 7   | 8840378  | G/A   | 0.10  | 0.295  | 0.059 | 5.28E-07  |
|             | R4B11FIP2    | rs34988394  | 10  | 119738984| T/C   | 0.16  | 0.234  | 0.050 | 2.83E-06  |
|             | CADMI        | rs4938201   | 11  | 115218713| G/A   | 0.39  | −0.162 | 0.035 | 3.31E-06  |
|             | RPSAP52      | rs11175889  | 12  | 66117678 | G/T   | 0.32  | 0.173  | 0.036 | 1.86E-06  |
|             | CDH11        | rs17358192  | 16  | 63892792 | G/T   | 0.24  | 0.184  | 0.039 | 2.05E-06  |
|             | FERMT1       | rs6076964   | 20  | 6210743  | T/C   | 0.06  | 0.341  | 0.075 | 4.65E-06  |
|             | CRYAA        | rs11701620  | 21  | 44601373 | G/C   | 0.06  | 0.346  | 0.073 | 1.84E-06  |
|             | LOC100271722 | rs12159453  | 22  | 46433442 | A/G   | 0.08  | −0.305 | 0.064 | 1.58E-06  |
| GWAS Traits | Nearest gene | Lead SNP | CHR | BP  | EA/OA | EAF  | BETA | SE  | p-value          |
|-------------|--------------|----------|-----|-----|-------|------|------|-----|----------------|
| Orexin      | PPAP2B       | rs944844 | 1   | 56891592 | G/A  | 0.16 | -0.099 | 0.021 | 2.30E-06 |
|             | SLC4A5       | rs3771728 | 2   | 74503190 | C/T  | 0.08 | -0.126 | 0.027 | 3.62E-06 |
|             | ABCA11P      | rs60941356 | 4   | 407189 | T/C  | 0.08 | -0.132 | 0.029 | 4.22E-06 |
|             | GABRB3       | rs8036016 | 15  | 26977581 | T/C  | 0.17 | 0.108 | 0.020 | 6.83E-08 |
|             | FLJ45079     | rs56201168 | 17  | 75734152 | C/T  | 0.06 | -0.162 | 0.033 | 7.10E-07 |
|             | RNF152       | rs34264102 | 18  | 5948629 | G/A  | 0.07 | 0.148 | 0.031 | 2.46E-06 |
|             | SKI1         | rs11702068 | 21  | 44768217 | T/C  | 0.19 | -0.093 | 0.020 | 2.27E-06 |
|             | MIAT         | rs9608521 | 22  | 27199237 | T/C  | 0.18 | -0.089 | 0.019 | 3.18E-06 |

SLS, Santiago Longitudinal Study; CHR, chromosome; BP, base pair; EA, effect allele; OA, other allele; EAF, effect allele frequency; SE, standard error

*Validated signal (In the validation set: $\beta = -0.191 \pm 0.065$, $P = 0.003$, EA = A, and EAF = 9%)
Table 3.

Associations of adiponectin and leptin levels with PRS\textsuperscript{Reported}, PRS\textsubscript{SLS}, and PRS\textsubscript{SLS+Novel}\textsuperscript{d} in SLS participants

| Biomarker | Model\textsuperscript{c} | PRS\textsuperscript{Reported} | PRS\textsubscript{SLS} | PRS\textsubscript{SLS+Novel} |
|-----------|----------------------------|-----------------------------|----------------------|-----------------------------|
|           | Beta\textsuperscript{d} | SE\textsuperscript{d} | p\textsuperscript{d} | R\textsuperscript{2} | Adj. R\textsuperscript{2} | Beta | SE | P | R\textsuperscript{2} | Adj. R\textsuperscript{2} | Beta | SE | P | R\textsuperscript{2} | Adj. R\textsuperscript{2} |
| Adiponectin | 1 | 0.027 | 0.006 | <0.0001 | 0.035 | 0.034 | 0.089 | 0.007 | <0.0001 | 0.253 | 0.252 | 0.080 | 0.005 | <0.0001 | 0.367 | 0.366 |
| | 2 | 0.028 | 0.006 | <0.0001 | 0.092 | 0.089 | 0.088 | 0.006 | <0.0001 | 0.305 | 0.302 | 0.080 | 0.004 | <0.0001 | 0.421 | 0.419 |
| | 3 | 0.028 | 0.006 | <0.0001 | 0.101 | 0.089 | 0.090 | 0.006 | <0.0001 | 0.324 | 0.316 | 0.082 | 0.004 | <0.0001 | 0.443 | 0.436 |
| | 4 | 0.029 | 0.006 | <0.0001 | 0.167 | 0.155 | 0.085 | 0.006 | <0.0001 | 0.352 | 0.342 | 0.079 | 0.004 | <0.0001 | 0.463 | 0.455 |
| Leptin | 2 | −0.017 | 0.025 | 0.4919 | 0.001 | −0.001 | 0.190 | 0.027 | <0.0001 | 0.082 | 0.080 | 0.231 | 0.020 | <0.0001 | 0.206 | 0.204 |
| | 3 | −0.015 | 0.025 | 0.5387 | 0.018 | 0.007 | 0.189 | 0.027 | <0.0001 | 0.098 | 0.088 | 0.230 | 0.019 | <0.0001 | 0.220 | 0.212 |
| | 4 | −0.020 | 0.022 | 0.3744 | 0.222 | 0.212 | 0.160 | 0.025 | <0.0001 | 0.278 | 0.268 | 0.194 | 0.018 | <0.0001 | 0.361 | 0.352 |

\textsuperscript{a}PRS\textsuperscript{Reported}: polygenic risk score (PRS) constructed by the previously reported SNPs; PRS\textsubscript{SLS}: PRS constructed by SLS-specific tagging SNPs (with the lowest p-value) within +/- 500kb region of the previously reported SNP; PRS\textsubscript{SLS+Novel}: PRS constructed by additional putative novel SNPs from the current study in addition to the PRS\textsubscript{SLS}

\textsuperscript{b}Adiponectin: natural log-transformed adiponectin level; leptin: rank-based normalized values of residuals from Tobit regression (sex-adjusted) for leptin levels.

\textsuperscript{c}Models:

- Adiponectin: [Model 1] log (Adiponectin levels) ~ PRS; [Model 2] log (Adiponectin levels) ~ PRS + Sex; [Model 3] log (Adiponectin levels) ~ PRS + Sex + PC1 + PC2 + PC3 + PC4 + PC5; [Model 4] log (Adiponectin levels) ~ PRS + Sex + PC1 + PC2 + PC3 + PC4 + PC5 + BMI Z-scores
- Leptin: [Model 2] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~ PRS; [Model 3] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~ PRS + PC1 + PC2 + PC3 + PC4 + PC5; [Model 4] Rank-based normalized values of residuals from Tobit model (sex-adjusted) ~ PRS + PC1 + PC2 + PC3 + PC4 + PC5 + BMI Z-score

\textsuperscript{d}Beta: a regression coefficient for PRS; SE: standard error of the regression coefficient; P: p-value
Table 4. The effects of biomarker PRS on downstream body fat percent (BF%) and glycemic traits (fasting blood glucose (FBG), fasting blood insulin (FBI), and insulin resistance (IR)) in SLS participants.

|                | Total effect<sup>a</sup> | Direct effect<sup>a</sup> | Indirect effect<sup>a</sup> |
|----------------|--------------------------|----------------------------|-----------------------------|
|                | Beta | 95% CL | P  | Beta | 95% CL | Beta | 95% CL |
| **Adiponectin PRS** |                |                |    |                |                |    |                |
| Glycemic Traits |                |                |    |                |                |    |                |
| FBG            | 0.001 | −0.081 | 0.082 | 0.9831 | 0.026 | −0.080 | 0.131 | −0.025 | −0.092 | 0.042 |
| FBI            | −0.124 | −0.208 | −0.040 | 0.0037<sup>b</sup> | −0.026 | −0.134 | 0.082 | −0.098 | −0.167 | −0.029 |
| HOMA-IR        | −0.117 | −0.201 | −0.033 | 0.0064<sup>b</sup> | −0.020 | −0.128 | 0.088 | −0.097 | −0.167 | −0.028 |
| BF%            | −0.135 | −0.198 | −0.071 | <0.0001<sup>b</sup> | −0.072 | −0.153 | 0.010 | −0.063 | −0.115 | −0.011 |
| **Leptin PRS** |                |                |    |                |                |    |                |
| Glycemic Traits |                |                |    |                |                |    |                |
| FBG            | −0.032 | −0.114 | 0.050 | 0.4406 | −0.064 | −0.154 | 0.027 | 0.032 | −0.008 | 0.071 |
| FBI            | 0.137 | 0.053 | 0.221 | 0.0014<sup>b</sup> | −0.009 | −0.098 | 0.079 | 0.146 | 0.100 | 0.192 |
| HOMA-IR        | 0.123 | 0.039 | 0.207 | 0.0043<sup>b</sup> | −0.021 | −0.110 | 0.068 | 0.144 | 0.098 | 0.190 |
| BF%            | 0.185 | 0.123 | 0.248 | <0.0001<sup>b</sup> | 0.006 | −0.054 | 0.066 | 0.180 | 0.139 | 0.221 |
| **Ghrelin PRS** |                |                |    |                |                |    |                |
| Glycemic Traits |                |                |    |                |                |    |                |
| FBG            | −0.061 | −0.142 | 0.020 | 0.1381 | 0.057 | −0.042 | 0.156 | −0.118 | −0.178 | −0.058 |
| FBI            | −0.217 | −0.299 | −0.134 | <0.0001<sup>b</sup> | 0.007 | −0.089 | 0.103 | −0.223 | −0.286 | −0.161 |
| HOMA-IR        | −0.215 | −0.298 | −0.133 | <0.0001<sup>b</sup> | 0.017 | −0.080 | 0.113 | −0.232 | −0.295 | −0.169 |
| BF%            | −0.064 | −0.127 | 0.000 | 0.0499 | 0.029 | −0.049 | 0.106 | −0.092 | −0.139 | −0.046 |
| **Orexin PRS** |                |                |    |                |                |    |                |
| Glycemic Traits |                |                |    |                |                |    |                |
| FBG            | −0.069 | −0.150 | 0.012 | 0.0939 | −0.059 | −0.145 | 0.026 | −0.010 | −0.038 | 0.018 |
|         | Total effect<sup>a</sup> | Direct effect<sup>a</sup> | Indirect effect<sup>a</sup> |
|---------|-------------------------|--------------------------|---------------------------|
|         | Beta | 95% CL | P  | Beta | 95% CL | Beta | 95% CL |
| FBI     | -0.001 | -0.085 | 0.083 | 0.9872 | 0.032 | -0.056 | 0.121 | -0.033 | -0.063 | -0.003 |
| HOMA-IR | -0.013 | -0.097 | 0.071 | 0.7588 | 0.019 | -0.069 | 0.108 | -0.033 | -0.063 | -0.003 |
| BF%     | 0.011 | -0.053 | 0.075 | 0.7320 | 0.031 | -0.037 | 0.099 | -0.020 | -0.042 | 0.003 |

Note: HOMA-IR (homeostatic model assessment of insulin resistance); 95% CL (Wald 95% Confidence Limits)

<sup>a</sup>Total effect: The overall effects of the biomarker PRS (constructed by putative novel SNPs in addition to SLS-specific tagging SNPs) on BF% or glycemic traits; direct effect: the effect of the biomarker PRS on BF% or glycemic traits after adjusting for the biomarker levels; indirect effect: the effect of the biomarker PRS on BF% or glycemic traits mediated through biomarker levels. All effects were estimated after adjusting for sex and 5 principal components of participants’ genetic composition. Adiponectin levels, ghrelin levels, orexin levels, FBG, FBI, and HOMA-IR were natural log-transformed. For leptin, rank-based inverse normalized residuals of a Tobit regression model adjusting for sex were used to account for the limit of detection issue. All the exposures, mediators, and outcomes were standardized.

- Model: Standardized natural log transformed glycemic traits or BF% ~ Standardized biomarker-PRS + standardized natural log-transformed biomarker levels (or rank-based normalized values of residuals from Tobit model (sex-adjusted) for leptin levels) + Sex + PC1 + PC2 + PC3 + PC4 + PC5
- Mediator: Standardized natural log-transformed biomarker levels (or rank-based normalized values of residuals from Tobit model (sex-adjusted) for leptin levels)
- Covariates: Sex, PC1, PC2, PC3, PC4, PC5

<sup>b</sup>Significant total effects of biomarker PRS on downstream BF% and glycemic traits (after correction for multiple testing p < 0.0125 (=0.05/4))